Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6c4a465d018d8fab3fc6d0858b74061 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-545 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6869 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-12 |
filingDate |
2011-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2019-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d42afa43dd10170da7d730ebe5ffe0dd |
publicationDate |
2019-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
ES-2699591-T3 |
titleOfInvention |
Antibodies against soluble human ST-2 and assays |
abstract |
An in vitro procedure for predicting the risk of death in one year in a subject, the procedure comprising: determining the level of gene 2 expressed by stimulation of human soluble growth (ST2), in a sample comprising blood, serum or plasma of a subject using an isolated antibody produced by a hybridoma deposited in the American Type Culture Collection (ATCC) and designated by the Patent Deposit Designation PTA-10432, or an antigen-binding fragment of an antibody produced by the hybridoma deposited in the ATCC and designated by the Patent Deposit Designation PTA-10432; and to identify a subject that has a high level of soluble human ST2 in the sample compared to a threshold level of soluble human ST2 that has a high risk of death in one year, or identify a subject that has a reduced or equal level of human soluble ST2 in the sample compared to the reference level of human soluble ST2 that You have a reduced risk of death in one year. |
priorityDate |
2010-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |